Biomarkers as Emerging Growth Area in Denmark
Biomarkers as an Emerging Growth Area in Denmark - a project driven by Biopeople
The aim of “Biomarkers as an emerging growth area" is to create better opportunities in Denmark for prevention of diseases, diagnosis and treatment by facilitating cross disciplinary collaboration in a partnership model of ICT, research and clinical development having focus on patient centricity, on the identification, validation and use of biomarkers.
In parallel, we explore how to build a "Danish infrastructure model" on biomarker research and development in a public-private partnership model among all stakeholders in order to strengthen biomarker innovation i Denmark.
Turn ideas and innovations into business opportunities
AWA is a leading intellectual property (IP) law firm with presence in Europe and Asia. We help our clients turn ideas and innovations into business opportunities. With a head office in Malmø, Sweden AWA offer full-service covering all IP practice areas and industries. The company has 3,600 clients in almost 60 countries – ranging from startups to owners of the world's most well-known brands and patent portfolios and 300 employees, including 180 IP professionals (120 patent attorneys, 40 attorneys-at-law, 20 other IP experts). Awa has 15 offices in Sweden, Denmark, China and Hong Kong, along with a representative office in Germany.
350 experts within all aspects of Intellectual Property
With more than 400 employees including IP experts, attorneys, paralegals and administrators.Zacco is Scandinavia's leading full-service intellectual property consultancy with 29 offices in Sweden, Denmark, Norway, Germany and the UK. The foundation for the international IP consulting firm that is today known as Zacco, was originally laid in 1870. After a merger in 2001 – between Hofman-Bang in Denmark, Stockholm Patentbyrå in Sweden and Bryns Patentkontor in Norway – the company adopted the name Zacco after one of its founders, Knut Yngve Zacco. In July 2009 Zacco merged with the long-standing and well-known IP consulting firm Albihns, forming the company Albihns.Zacco, which in September 2012 changed its name to Zacco.
Three decades of biomedical expertise and Pioniergeist
For almost 30 years, Miltenyi Biotec has played an important role in the design, development, manufacture, and integration of products that empower the advancement of biomedical research and enable cell and gene therapy. The company looks back at three decades of biomedical expertise and Pioniergeist. Throughout this time, Miltenyi Biotec have continuously worked on the advancement of our technologies and collaborated with researchers around the world to push the boundaries of what is technically possible. As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products for research, clinical, and manufacturing needs.
Everything started in Germany where the headquarters are still located in Bergisch Gladbach. The company has established subsidiaries in six areas of Europe with a Nordic office in Luns, Sweden. This office serves the Baltic countries, including Sweden, Denmark, Norway, Finland, Iceland, Lithuania, Latvia, and Estonia.
A global leader in life sciences, diagnostics, and applied chemical market
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide.
In 2012 Agilent acquired Danish Dako, a leading provider of reagents, instruments, software and expertise. For more than half a century, Dako products have helped pathologists make accurate diagnoses and determine the most effective treatment for cancer patients. Scientific advancements and groundbreaking discoveries from Dako included the first conjugated antibodies; the first automation in IHC, H&E and special stains; and the first companion diagnostic test.
Cross-linking science and market ideas
Bioneer A/S is a not-for-profit organization and a subsidiary of the Technical University of Denmark (DTU) and is approved by the Danish Ministry of Science and Technology as an authorised provider of technological services – a GTS entity. Bioneer has a two-fold mission - to provide tools and technologies that facilitate early implementation in the Danish health sector of new therapeutic strategies and to contribute to making Denmark a front-runner in very early commercialisation of biomedical research as a means to grow the Danish biotech industry.
With a staff of 45 dedicated and highly skilled persons, state-of-the-art facilities in the Scion-DTU Science Park in Copenhagen, and a history of 25 years of operation, Bioneer is fit to fulfil its dual role as commercial entity with a societal obligation.